Topics:

Phase I Trial of NPI-0052 Begins

Phase I Trial of NPI-0052 Begins

SAN DIEGO, Calif—Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.